All data are based on the daily closing price as of November 14, 2024
h
Hisamitsu Pharmaceutical
4530.TSE
27.18 USD
-0.52
-1.88%
Overview
Last close
27.18 usd
Market cap
1.99B usd
52 week high
36.65 usd
52 week low
22.89 usd
Target price
28.85 usd
Valuation
P/E
21.782
Forward P/E
N/A
Price/Sales
2.0833
Price/Book Value
1.1515
Enterprise Value
1.24B usd
EV/Revenue
1.2877
EV/EBITDA
7.3353
Key financials
Revenue TTM
962.85M usd
Gross Profit TTM
449.21M usd
EBITDA TTM
124.80M usd
Earnings per Share
1.26 usd
Dividend
0.82 usd
Total assets
350.48B usd
Net debt
-112.46B usd
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.